key: cord-0271445-phce79oi authors: Miranda, Jamilet; Bringas, Ricardo; Fernández-de-Cossio, Jorge; Perera, Yasser title: CIGB-300 synthetic peptide, an antagonist of CK2 kinase activity, as a treatment for Covid-19. A computational biology approach date: 2021-07-26 journal: bioRxiv DOI: 10.1101/2021.07.26.453805 sha: 8df7b4edf2f4976ca02e3353af4286f78889c335 doc_id: 271445 cord_uid: phce79oi Drug repositioning became the first choice for treating Covid-19 patients due to the urgent need to deal with the pandemic. Similarities in the hijacking mechanisms used by SARS-CoV-2 and several type of cancer, suggest the repurposing of cancer drugs to treat Covid-19. CK2 kinase antagonists have been proposed for the treatment of cancer. A recent study in cells infected with SARS-CoV-2 virus found a significant CK2 kinase activity, and the use of a CK2 inhibitor showed antiviral responses. CIGB-300, originally designed as an anticancer peptide, is an antagonist of CK2 kinase activity that binds to CK2 phospho-acceptor sites. Recent preliminary results show an antiviral activity of CIGB-300 versus a surrogate model of coronavirus. Here we present a computational biology study that provides evidences at the molecular level of how CIGB-300 might interfere with SARS-CoV-2 life cycle inside infected human cells. First, from SARS-CoV studies, we infer the potential incidence of CIGB-300 in SARS-CoV-2 interference on immune response. Next, from the analysis of multiple Omics data, we propose the action of CIGB-300 since early stage of viral infections perturbing the virus hijacking of RNA splicing machinery. It was also predicted the interference of CIGB-300 in virus-host interactions responsible for the high infectivity and the particular immune response to SARS-CoV-2 infection. Further, we provide evidences of CIGB-300 attenuation of phenotypes related to muscle, bleeding, coagulation and respiratory disorders. SARS-CoV-2 currently spread world-wide showing high infectivity and transmissibility. 45 Due to the urgency of finding effective therapeutics treatments in the shortest possible 46 time, drug repurposing emerged as the first option [1, 2] . The huge amount of data so far 47 generated permit the re-consideration of drugs already evaluated for other diseases, 48 which might have advanced toxicological, preclinical and/or clinical studies. 49 Since the genomic sequence of SARS-CoV-2 was made available in January 2020 [3] , 50 diversity of technique and laboratory models has been profusely applied to the study of 51 SARS-CoV-2 replication and infectivity. with CIGB-300 showed a significant reduction of virus production suggesting B23 as an 103 attractive target for antiviral drugs. Lobaina and Perera [12] also proposed B23 as a 104 potential target in antiviral therapies. 105 With this background, CIGB-300 was tested for its safety and clinical benefits in Covid- interaction of CIGB-300 with BCoV nucleocapsid protein(N) was also revealed. Functional enrichment found cytoskeleton reorganization and protein folding as the 112 major disturbed biological processes. Here we present an in silico analysis of SARS-CoV and SARS-CoV-2 viral infection. We have been also implicated in the inhibition of type I interferon signaling pathway [19] . A sequence alignment of N protein from SARS-CoV and SARS-CoV-2 viruses show a 132 high similarity (Fig 1) . N Protein consists of two structural domains (Fig 1) : the N- and Ser251 were noted as putative phospho-acceptors for CK2 (see Fig 1) , though 147 neither has been corroborated experimentally. We collected a total of 33 148 phosphorylation sites for SARS-CoV-2 N protein (see Fig 1 and binds KPNA2. In this way, the chaperon function of KPNB1 through the nuclear pore is 189 interfered, and STAT1 signaling is interrupted (Fig 2B) . respectively. The last two mutants, Orf6 54-58Ala and Orf6 59-63Ala , comprising the ten C-terminal amino acids, did not retain KPNA2 and as consequence, STAT1 function was 196 unaffected. The first mutant Orf6 49-53Ala was still able to retain KPNA2. So, the last ten 197 aminoacids were responsible for KPNA2 binding and, as consequence, for KPNB1 198 recruitment. Mutant M2 of Lei et al. [28] include Asp53 residue at position +3 relative to Ser50, and this position is known to be important for the recognition of CK2. Therefore, we strongly 218 suggest that the possible binding of CIGB-300 to this phospho-acceptor motif would 219 interfere the interaction of Orf6 C-terminus with KPNA2; avoiding its retention in the 220 ER/Golgi membrane, without interfering KPNA2 chaperon activity of carrying STAT1 221 complex to the nucleus ( Fig 2C) . In this regard, CIGB-300 could exhibit an effect that 222 other CK2 antagonists that target CK2 won't. Taking all these together, we suggest that CIGB-300 intervene SRSF1 role in SARS- CoV-2 protein synthesis interfering its phosphorylation by SRPK1 kinase. shown those sites whose phosphorylation was increased by SARS-CoV-2 infection. Evaluating how CIGB-300 may interfere host-host protein interactions implicated in 409 virus-induced mechanisms, we found that 68 proteins (SC2_300 set from now on) have 410 activated phospho-acceptor sites in at least two of the four phosphoproteomic studies, 411 which were inhibited by CIGB-300 (see S2 Table) . The protein-protein interactions (PPI) 412 network built with these proteins is shown in Fig 8. A majority of the nodes in the S3 Table) . The five proteins with higher degree are also highlighted. In this network HSPB1 heat shock protein (alias HSP27) is one of the highest degree CoV-2. First, we saw it as the host protein with a higher correlation of expression to viral proteins, in particular to Orf6. Second, we identified B23 as a highly connected 473 node in a network of proteins consistently upregulated by SARS-CoV-2 infection and 474 inhibited by CIGB-300, which is related to Cell Cycle pathway (Fig 8) . Third, it was part 475 of a phenotype network related to respiratory, bleeding and coagulation disorders, • Interference of IFN signaling, which is responsible for a weak immune response. • Early stages of virus kidnapping of RNA processing, which plays an essential 517 role in virus genome replication and translation. • Aggresome accumulation and its role in Inflammation and fibrosis commonly 519 observed in severe Covid-19 patients. • Phenotypes related to muscle, bleeding, coagulation and respiratory disorders. Additional statistical analysis and graphs were generated and plotted using GraphPad 607 608 Drug repositioning is an 611 alternative for the treatment of coronavirus COVID-19 Artificial intelligence in COVID-19 drug 613 repurposing A pneumonia outbreak associated with a new 615 coronavirus of probable bat origin Imbalanced Host Response 617 to SARS-CoV-2 Drives Development of COVID-19 A SARS-CoV-2 protein interaction 619 map reveals targets for drug repurposing The Global Phosphorylation 621 Landscape of SARS-CoV-2 Infection Safety of intravenous application of CIGB-300 in patients with hematological malignancies. 624 EHPMA study. . Revista Cubana de Hematología Phase I Study of CIGB-300 Administered Intravenously in Patients 626 with Relapsed/Refractory Solid Tumors CIGB-300 anticancer peptide 628 regulates the protein kinase CK2-dependent phosphoproteome Anticancer peptide CIGB-300 binds 630 to nucleophosmin/B23, impairs its CK2-mediated phosphorylation, and leads to apoptosis 631 through its nucleolar disassembly activity Biophysical Characterization of 633 Nucleophosmin Interactions with Human Immunodeficiency Virus Rev and Herpes Simplex Virus 634 US11 Implication of B23/NPM1 in Viral Infections, Potential Uses of B23/NPM1 636 Inhibitors as Antiviral Therapy Treatment with an Anti-CK2 638 Synthetic Peptide Improves Clinical Response in COVID-19 Patients with Pneumonia. A 639 Randomized and Controlled Clinical Trial Targeting of Protein Kinase CK2 641 Elicits Antiviral Activity on Bovine Coronavirus Infection Actionable Cytopathogenic Host 643 Responses of Human Alveolar Type 2 Cells to SARS-CoV-2 Growth Factor Receptor Signaling 645 Inhibition Prevents SARS-CoV-2 Replication Multilevel proteomics reveals host 647 perturbations by SARS-CoV-2 and SARS-CoV Nucleocapsid phosphorylation and RNA helicase DDX1 recruitment 649 enables coronavirus transition from discontinuous to continuous transcription The ORF6, ORF8 and nucleocapsid proteins of 652 SARS-CoV-2 inhibit type I interferon signaling pathway Modular organization of SARS coronavirus 654 nucleocapsid protein Characterisation of the 656 transcriptome and proteome of SARS-CoV-2 reveals a cell passage induced in-frame deletion of 657 the furin-like cleavage site from the spike glycoprotein The severe acute respiratory 659 syndrome coronavirus nucleocapsid protein is phosphorylated and localizes in the cytoplasm by 660 14-3-3-mediated translocation Antibody detection of SARS-CoV spike and 662 nucleocapsid protein A systemic and molecular study of 664 subcellular localization of SARS-CoV-2 proteins Interferon-stimulated genes: a complex web of host 666 defenses Severe acute respiratory 668 syndrome coronavirus ORF6 antagonizes STAT1 function by sequestering nuclear import factors 669 on the rough endoplasmic reticulum/Golgi membrane SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 671 function as potent interferon antagonists Activation and evasion of type I interferon 673 responses by SARS-CoV-2 Proteomics of SARS-CoV-2-infected 675 host cells reveals therapy targets The nucleocapsid protein of SARS-associated 677 coronavirus inhibits B23 phosphorylation Quantitative analysis of a 679 phosphoproteome readily altered by the protein kinase CK2 inhibitor quinalizarin in HEK-293T 680 cells SARS-CoV-2 Orf6 hijacks 682 Nup98 to block STAT nuclear import and antagonize interferon signaling Matrin 3 binds and stabilizes 685 mRNA FUS interacts with nuclear matrix-associated protein SAFB1 as well 687 as Matrin3 to regulate splicing and ligand-mediated transcription Posttranscriptional 689 Regulation of HIV-1 Gene Expression during Replication and Reactivation from Latency by 690 Nuclear Matrix Protein MATR3 Involvement of phosphorylation in binding of nuclear 692 scaffold proteins from rat liver to a highly repetitive DNA component Matrin 3 in neuromuscular disease: physiology and pathophysiology. 695 JCI Insight 6 Mutations in the Matrin 3 gene cause 697 familial amyotrophic lateral sclerosis ) p38delta MAPK regulates aggresome biogenesis by 699 phosphorylating SQSTM1 in response to proteasomal stress Cytosolic PINK1 promotes the targeting of 701 ubiquitinated proteins to the aggresome-autophagy pathway during proteasomal stress Role of Cigarette Smoke-Induced Aggresome Formation 704 in Chronic Obstructive Pulmonary Disease-Emphysema Pathogenesis 2020) p62/SQSTM1 accumulation due to degradation inhibition 707 and transcriptional activation plays a critical role in silica nanoparticle-induced airway 708 inflammation via NF-kappaB activation Cystic fibrosis: a disorder 710 with defective autophagy Defective CFTR induces 712 aggresome formation and lung inflammation in cystic fibrosis through ROS-mediated autophagy 713 inhibition DIO-1 is a gene 715 involved in onset of apoptosis in vitro, whose misexpression disrupts limb development Hemoglobin 718 overexpression and splice signature as new features of inflammatory breast cancer? Death-inducer obliterator 1 (DIDO1) silencing 721 suppresses growth of bladder cancer cells through decreasing SAPK/JNK signaling cascades BAP1 maintains chromosome stability by stabilizing DIDO1 in 724 renal cell carcinoma Protein kinase CK2: a challenge to canons A proposed molecular mechanism for pathogenesis of 727 severe RNA-viral pulmonary infections Adaptable molecular 729 interactions guide phosphorylation of the SR protein ASF/SF2 by SRPK1 Human papillomavirus 731 type 16 infection activates the host serine arginine protein kinase 1 (SRPK1) -splicing factor axis Inactivation of the SR protein splicing factor ASF/SF2 results in genomic 734 instability Phosphorylation mechanism and structure of serine-arginine protein 736 kinases Protein kinase CK2 phosphorylates and activates the SR protein-738 specific kinase 1 Heat Shock Protein 27 Plays a Pivotal Role in 740 Myofibroblast Differentiation and in the Development of Bleomycin-Induced Pulmonary 741 Fibrosis Inhibition of HSP27 blocks 743 fibrosis development and EMT features by promoting Snail degradation Ivermectin inhibits HSP27 and 745 potentiates efficacy of oncogene targeting in tumor models The FDA-approved drug ivermectin 747 inhibits the replication of SARS-CoV-2 in vitro A five-day course of ivermectin 749 for the treatment of COVID-19 may reduce the duration of illness Evaluation of the effectiveness 751 and safety of adding ivermectin to treatment in severe COVID-19 patients The prognostic value of elevated 754 creatine kinase to predict poor outcome in patients with COVID-19 -A systematic review and 755 meta-analysis Weakness and elevated creatinine kinase as the 757 initial presentation of coronavirus disease 2019 (COVID-19) The impact of SARS-CoV-2 on skeletal muscles CoV-2 infection is common and independent of severity of initial infection Case Report: Myopathy in 765 Critically Ill COVID-19 Patients: A Consequence of Hyperinflammation COVID-19 coagulopathy: is it disseminated intravascular coagulation? Intern 767 Disseminated intravascular coagulation: A devastating systemic disorder 769 of special concern with COVID-19 Identification 771 and characterization of nucleophosmin/B23/numatrin which binds the anti-oncogenic 772 transcription factor IRF-1 and manifests oncogenic activity Selective regulation of type II interferon-inducible genes 774 by NPM1/nucleophosmin Phosphomimics destabilize Hsp27 776 oligomeric assemblies and enhance chaperone activity Role of protein kinase CK2 phosphorylation in the 778 molecular chaperone activity of nucleolar protein b23 BioGRID: a general repository 782 for interaction datasets 2014: mutations, 784 PTMs and recalibrations The CLUSTAL_X windows 786 interface: flexible strategies for multiple sequence alignment aided by quality analysis tools microarray software suite Significance analysis of microarrays applied to the ionizing 791 radiation response PGC-1alpha-responsive 793 genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes Gene set enrichment 796 analysis: a knowledge-based approach for interpreting genome-wide expression profiles Cytoscape: a software environment 799 for integrated models of biomolecular interaction networks Cytoscape 2.8: new features for data 801 integration and network visualization BisoGenet: a new tool 803 for gene network building, visualization and analysis The reactome pathway knowledgebase. 805 GeneCodis3: a non-redundant and 807 modular enrichment analysis tool for functional genomics BiNGO: a Cytoscape plugin to assess overrepresentation of 809 gene ontology categories in biological networks Bidimensional clustering of most differentially expressed proteins 813 resulting from the analysis of proteomic data of CaCo-2 cells infected by SARS Horizontal axis represents samples at different time 815 points and vertical axis represent differentially expressed proteins N phospho-acceptor sites reported in four phosphoproteomics List of 102 phosphosites activated in at least two of the four 820 phosphoproteomic studies